MX338373B - Composicion antipsicotica inyectable de liberacion controlada. - Google Patents

Composicion antipsicotica inyectable de liberacion controlada.

Info

Publication number
MX338373B
MX338373B MX2012013937A MX2012013937A MX338373B MX 338373 B MX338373 B MX 338373B MX 2012013937 A MX2012013937 A MX 2012013937A MX 2012013937 A MX2012013937 A MX 2012013937A MX 338373 B MX338373 B MX 338373B
Authority
MX
Mexico
Prior art keywords
drug
composition
day
plasma levels
antipsychotic
Prior art date
Application number
MX2012013937A
Other languages
English (en)
Other versions
MX2012013937A (es
Inventor
Aduriz Ibon Gutierro
Ochoa María Teresa Gómez
Original Assignee
Rovi Lab Farmaceut Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43301889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338373(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rovi Lab Farmaceut Sa filed Critical Rovi Lab Farmaceut Sa
Publication of MX2012013937A publication Critical patent/MX2012013937A/es
Publication of MX338373B publication Critical patent/MX338373B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

La presente invención se refiere a una composición que puede utilizarse para administrar un fármaco antipsicótico tal como risperidona en forma de un implante inyectable biodegradable que se forma in-situ para liberación prolongada, proporcionando niveles plasmáticos terapéuticos desde el primer día. La composición está en forma de suspensión de fármaco en una solución de copolímero o copolímeros biodegradables y biocompatibles utilizando disolventes miscibles en agua, que se administra en forma líquida. Una vez que la composición se pone en contacto con los fluidos corporales, la matriz polimérica se endurece reteniendo el fármaco, formando un implante sólido o semisólido que libera el fármaco de forma continuada. Pueden lograrse niveles terapéuticos del fármaco en plasma desde el primer día hasta al menos 14 días o más.
MX2012013937A 2010-05-31 2011-05-31 Composicion antipsicotica inyectable de liberacion controlada. MX338373B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382154.2A EP2394664B1 (en) 2010-05-31 2010-05-31 Antipsychotic injectable depot composition
PCT/EP2011/059000 WO2011151355A1 (en) 2010-05-31 2011-05-31 Antipsychotic injectable depot composition

Publications (2)

Publication Number Publication Date
MX2012013937A MX2012013937A (es) 2013-02-11
MX338373B true MX338373B (es) 2016-04-13

Family

ID=43301889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013937A MX338373B (es) 2010-05-31 2011-05-31 Composicion antipsicotica inyectable de liberacion controlada.

Country Status (32)

Country Link
US (2) US10085936B2 (es)
EP (2) EP2394664B1 (es)
JP (1) JP5882993B2 (es)
KR (1) KR101784330B1 (es)
CN (1) CN103002917B (es)
AP (1) AP3524A (es)
AU (1) AU2011260318B2 (es)
BR (1) BR112012030686B1 (es)
CA (1) CA2800111C (es)
CL (1) CL2012003350A1 (es)
CY (2) CY1117969T1 (es)
DK (2) DK2394664T3 (es)
EA (1) EA024155B1 (es)
ES (2) ES2589106T3 (es)
HR (2) HRP20161049T1 (es)
HU (2) HUE029895T2 (es)
IL (1) IL223129A (es)
LT (2) LT2394664T (es)
MA (1) MA34296B1 (es)
ME (1) ME02501B (es)
MX (1) MX338373B (es)
MY (1) MY161930A (es)
NZ (1) NZ604342A (es)
PL (2) PL2394664T3 (es)
PT (2) PT2394664T (es)
RS (1) RS55190B1 (es)
SG (1) SG185775A1 (es)
SI (2) SI2394664T1 (es)
SM (2) SMT201600320B (es)
UA (1) UA108885C2 (es)
WO (1) WO2011151355A1 (es)
ZA (1) ZA201209346B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
NZ597621A (en) 2007-05-25 2013-06-28 Tolmar Therapeutics Inc Sustained delivery formulations of risperidone compounds
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
PL2394663T3 (pl) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
ES2589106T3 (es) 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
ES2878112T3 (es) * 2011-05-31 2021-11-18 Farm Rovi Lab Sa Formulación de implante de risperidona y/o paliperidona
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EP2986278A1 (en) 2013-03-11 2016-02-24 DURECT Corporation Injectable controlled release composition comprising high viscosity liquid carrier
WO2016199170A2 (en) * 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
CN110420212A (zh) * 2019-08-19 2019-11-08 韩自勤 一种用于治疗精神分裂症组合物及其制备方法
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
SI0729357T1 (en) 1993-11-19 2005-06-30 Janssen Pharmaceutica N.V. Microencapsulated 1,2-benzazoles
DE69735384T2 (de) 1996-12-20 2006-08-10 Alza Corp., Mountain View Gelzusammensetzungen und verfahren
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
EP1248596B1 (de) * 2000-01-11 2007-03-07 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
KR20050083605A (ko) * 2002-07-31 2005-08-26 알자 코포레이션 주사 가능한 다원성 중합체 데포트 조성물 및 이의 용도
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
CA2819769C (en) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
LT3660073T (lt) 2007-02-15 2023-10-10 Tolmar International Limited Poli(laktidas-ko-glikolidas) su lėtu pradiniu atsipalaidavimu
CA2686137C (en) * 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
NZ597621A (en) * 2007-05-25 2013-06-28 Tolmar Therapeutics Inc Sustained delivery formulations of risperidone compounds
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
CA2731316C (en) * 2008-08-12 2017-10-03 Novartis Ag Pharmaceutical compositions
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
ES2589106T3 (es) 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
PL2394663T3 (pl) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
SI2529757T1 (sl) 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
ES2878112T3 (es) 2011-05-31 2021-11-18 Farm Rovi Lab Sa Formulación de implante de risperidona y/o paliperidona

Also Published As

Publication number Publication date
CA2800111C (en) 2018-05-22
CN103002917B (zh) 2016-04-27
WO2011151355A1 (en) 2011-12-08
JP5882993B2 (ja) 2016-03-09
US20180221272A1 (en) 2018-08-09
HRP20161049T1 (hr) 2016-12-30
AU2011260318A1 (en) 2013-01-10
PL2394664T3 (pl) 2016-12-30
MY161930A (en) 2017-05-15
PT2575890T (pt) 2016-09-06
HRP20161100T1 (hr) 2016-11-04
SI2575890T1 (sl) 2016-10-28
US20130171202A1 (en) 2013-07-04
MX2012013937A (es) 2013-02-11
JP2013528612A (ja) 2013-07-11
AP3524A (en) 2016-01-11
SMT201600320B (it) 2016-11-10
LT2575890T (lt) 2016-09-26
MA34296B1 (fr) 2013-06-01
SG185775A1 (en) 2013-01-30
AP2012006626A0 (en) 2012-12-31
CL2012003350A1 (es) 2013-10-18
CN103002917A (zh) 2013-03-27
ES2589106T3 (es) 2016-11-10
US10085936B2 (en) 2018-10-02
PT2394664T (pt) 2016-09-06
ME02501B (me) 2017-02-20
KR101784330B1 (ko) 2017-10-11
ZA201209346B (en) 2013-08-28
SMT201600321B (it) 2016-11-10
BR112012030686B1 (pt) 2022-11-01
EP2575890B1 (en) 2016-06-01
BR112012030686A2 (pt) 2020-08-25
US10182982B2 (en) 2019-01-22
IL223129A (en) 2016-02-29
EA024155B1 (ru) 2016-08-31
EP2394664B1 (en) 2016-06-01
CA2800111A1 (en) 2011-12-08
LT2394664T (lt) 2016-09-26
EA201201569A1 (ru) 2013-04-30
AU2011260318B2 (en) 2014-11-27
CY1117964T1 (el) 2017-05-17
HUE029895T2 (en) 2017-04-28
UA108885C2 (uk) 2015-06-25
DK2575890T3 (en) 2016-09-12
KR20130118742A (ko) 2013-10-30
EP2394664A1 (en) 2011-12-14
CY1117969T1 (el) 2017-05-17
EP2575890A1 (en) 2013-04-10
ES2592527T3 (es) 2016-11-30
RS55190B1 (sr) 2017-01-31
HUE029056T2 (en) 2017-02-28
IL223129A0 (en) 2013-02-03
NZ604342A (en) 2014-11-28
PL2575890T3 (pl) 2016-12-30
DK2394664T3 (en) 2016-09-12
SI2394664T1 (sl) 2016-10-28

Similar Documents

Publication Publication Date Title
MY161930A (en) Antipsychotic injectable depot composition
NZ604026A (en) Injectable flowable composition comprising buprenorphine
MX2009004856A (es) Matriz polimerica insoluble en agua para suministro de farmaco.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
RS53205B (en) IMPLANTABLE PALIPERIDON FORMULATION
DK1786400T3 (da) Farmaceutiske sammensætning til tilförsel med kontrolleret frigivelse af biologisk aktive forbindelser
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
PH12014502667B1 (en) Risperidone or paliperidone implant formulation
IN2012DN05099A (es)
HK1160779A1 (en) Cdk inhibitor for the treatment of mesothelioma
ECSP088240A (es) Composición de trazodona para administración una vez por día
WO2009091576A3 (en) Parenteral formulations of dopamine agonists
IN2013MN02384A (es)
WO2008054772A3 (en) Implantable elastomeric caprolactone depot compositions and uses thereof
EA201401348A1 (ru) Технология приготовления имплантируемой формы палиперидона
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
WO2011109732A3 (en) Reverse thermal gels and uses therefor
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
TR201010683A1 (tr) Vildagliptin formülasyonları.
UY31343A1 (es) Composicion con una combinacion de principios activos para el tratamiento del estrenimiento
MX2009014178A (es) Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
MX2009003092A (es) Composiciones y metodos para suministro de farmaco dirigido a ph.
WO2011056653A3 (en) Clonidine formulations having antimicrobial properties

Legal Events

Date Code Title Description
FG Grant or registration